The practical implications of this difference extend to manufacturing, patent protection, dosing flexibility, and potentially even clinical outcomes
Figure 2 5 Immune regulatory mechanisms of PEFs in the TME PEFs (IRE and nsPEF) drive anti-tumor responses by systemically reshaping the myeloid immune landscape: They significantly reduce MDSCs proportions ( + TAM-mediated immunosuppression ( + monocytes into dendritic cells ( 2 NSs captures tumor antigens to form in situ vaccines that promote DC migration ( Figure 3 )
As always, patient education, informed consent, rigorous monitoring and a conservative, evidence-based approach are essential
We'll create a plan that addresses your full picture
Archived from the original on June 17, 2023
no completed randomized controlled human trial exists for any indication